A Phase 2 interventional study of Monosialoganglioside Ganglioside and Methylprednisolone (Steroid Hormone) in Cerebral Radiation Necrosis, sponsored by Zhejiang Cancer Hospital. Status unknown at 1 site in China. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2017-03-01.
Sponsored by Zhejiang Cancer Hospital · Phase 2, Interventional, and Treatment
Monosialoganglioside Ganglioside in Cerebral Radiation Necrosis
A prospective phase II trial was conducted to test the efficacy of monosialoganglioside ganglioside for the treatment of cerebral radiation necrosis
Zhejiang Cancer Hospital is the lead sponsor of 281 studies on the registry; 116 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Pulse steroid, methylprednisolone, was administered by intravenous infusion over 3 consecutive days. Three grams of methylprednisolone was given in each cycle. Administration of 1 g was infused over 1 h daily for 3 days on an in-patient basis, which then tailed off in 10 days with administration of oral prednisolone.
Drug: Methylprednisolone (Steroid Hormone) · Drug: Prednisolone
Monosialoganglioside ganglioside was given at 100 mg/time, once a day for 2 months.
Drug: Monosialoganglioside Ganglioside
Monosialoganglioside ganglioside was given at 100 mg/time, once a day for 2 months.
Pulse steroid, methylprednisolone, was administered by intravenous infusion over 3 consecutive days. Three grams of methylprednisolone was given in each cycle. Administration of 1 g was infused over 1 h daily for 3 days on an in-patient basis, which then tailed off in 10 days with administration of oral prednisolone.
Objective response rate
Response Evaluation Criteria in Solid Tumors (RECIST) were used.
Time frame: From the first day of treatment, to 3 months after treatment
Plan to share: No
No publications or documents are linked to this record.
This study is status unknown, as verified in Jan 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.